“…This was unexpected as zimelidine, and particularly its active metabolite norzimelidine, has been found to be a more potent inhibitor of 5-HT uptake in vitro than alaproclate (Fuxe et al 1977). However, there are indications that the potency of alaproclate may have been underestimated, since it has been shown to be more potent than zimelidine in behavioural studies (Fuxe et al 1977), and Horn & Watts (1985) found that under similar conditions to those used in the present paper, alaproclate, but not zimelidine, affected the 5-HIAA/5-HT ratio in the raphe nucleus of model 2. More recently, it has been reported that zimelidine has no effect on endocrine function in man (Syvalahti, Nagy & Van Praag, 1979;Kletzky, St Michel, Mashchak & Coleman, 1983).…”